Andere Sprachen Crescita Therapeutics Inc. OTC Markets

Aktien

A2AD5R

CA2258471028

CRRTF

Markt geschlossen - OTC Markets Andere Börsenplätze 20:14:05 02.04.2024			% 5 Tage	% 1. Jan.
0,32 ^USD	-0,16 %		-.--%	+14,29 %

08.05.	Crescita Therapeutics Q1 Verlust weitet sich aus, Umsatz steigt	MT
08.05.	Crescita Therapeutics Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Crescita Therapeutics Q1 Loss Widens, Revenue Rises	08.05.
Crescita Therapeutics Brief: Q1 Revenue was $4.996 Million	08.05.
Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023.	08.05.
Crescita Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
Crescita Reports First Quarter 2024 Results	08.05.
Crescita Therapeutics Reports Q4 Net Loss of $0.01 Per Share	13.03.
Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023.	13.03.
Crescita Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13.03.
Crescita Therapeutics Brief: Q4 EPS Basic and Diluted Loss $0.01	13.03.
Crescita Reports Q4 and Fiscal 2023 Results	13.03.
Crescita Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	13.03.
North American Morning Briefing : Stock Futures -2-	13.03.
Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023.	08.11.
Crescita Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08.11.
Crescita Reports Third Quarter 2023 Results	08.11.
Crescita Therapeutics Obtains TSX Approval for Normal Course Issuer Bid	29.08.23
Crescita Therapeutics Brief: Announced Approval of Normal Course Issuer Bid	29.08.23
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid	29.08.23
Crescita Therapeutics Inc. announces an Equity Buyback for 1,821,616 shares, representing 8.94% of its issued share capital.	29.08.23
Crescita Therapeutics Inc. authorizes a Buyback Plan.	29.08.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Crescita Therapeutics Inc. OTC Markets

Aktien

A2AD5R

CA2258471028

CRRTF

Andere Sprachen

Filter